ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Brian D. Dayton et al.|Nature Medicine|2013Cited by 3k
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182
HOXD10 attenuates renal fibrosis by inhibiting NOX4-induced ferroptosisXin Li, Hong Ding|Cell Death and Disease|2024Cited by 27